Ilsung Is Valuation

Q: What is the Fair Price of A003120 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A003120 (₩16050) is trading below our estimate of [[fair value]] (₩29741.85)

Is A003120 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A003120 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A003120 (₩16050) is trading below our estimate of fair value (₩29741.85)

Significantly Below Fair Value: A003120 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A003120?

Key metric: As A003120 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A003120. This is calculated by dividing A003120's market cap by their current revenue.
What is A003120's PS Ratio?
PS Ratio	1.5x
Sales	₩73.22b
Market Cap	₩111.85b

A003120 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A003120's PS Ratio compare to its peers?

The above table shows the PS ratio for A003120 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.7x
A009300 Sam-A Pharm	1x	n/a	₩105.7b
A066700 Theragen EtexLtd	0.4x	n/a	₩108.7b
A330350 WITHUS PHARMACEUTICALLTD	0.8x	n/a	₩89.1b
A006620 DongKoo Bio & Pharma	0.6x	n/a	₩136.8b
A003120 Ilsung Is	1.5x	n/a	₩111.9b

Price-To-Sales vs Peers: A003120 is expensive based on its Price-To-Sales Ratio (1.5x) compared to the peer average (0.7x).

Price to Sales Ratio vs Industry

How does A003120's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	US$158.67m
A002620 Jeil Pharma Holdings	0.2x	n/a	US$92.36m
A000230 Ildong Holdings	0.1x	n/a	US$57.08m

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A003120 is expensive based on its Price-To-Sales Ratio (1.5x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A003120's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A003120 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A003120's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩128,800.00

2.1%

-41.2%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

-4.8%

n/a

Ildong Pharmaceutical

₩339.7b

Develops, manufactures, and sells pharmaceutical products in South Korea.

A249420

₩12,160.00

0.08%

-29.3%